SVA
Sinovac Biotech Ltd
NASDAQ: SVA · HEALTHCARE · BIOTECHNOLOGY
$6.47
+0.00% today
Updated 2026-04-29
Market cap
$642.44M
P/E ratio
6.66
P/S ratio
1.83x
EPS (TTM)
$0.97
Dividend yield
850.00%
52W range
$6 – $6
Volume
—
Sinovac Biotech Ltd (SVA) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$6.47
12-Month target
$8.08
2030 Target
$12.63
Intrinsic (DCF)
$22.06
Financial forecast
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.2B | $0.5B | $19.4B | $1.5B | $0.4B | $0.5B | $0.6B | $0.7B | $0.8B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 14.31% (capped 20%) · P/E: 6.66x (capped 25x) · Margin: 21.60%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.